**INVESTOR NEWSLETTER**

**November 2019**

**STRATEGY SPOTLIGHT**

**FreeStyle Libre Improving Patient Outcomes in the U.K.**

Medscape Today reported that changes to funding for FreeStyle Libre on the NHS in England are leading to rapid adoption of the device, which is improving patient outcomes. Analysis of more than 6,500 patients showed significant reductions in time spent in hypoglycemia and hypoglycemia-related hospital admissions.

**Integrating FreeStyle Libre with Insulin Delivery Technologies**

We recently joined forces with Sanofi, Omada Health and Tandem Diabetes Care to integrate our FreeStyle Libre glucose monitoring system with insulin delivery systems to create a connected device experience. These collaborations add to our partnerships with Bigfoot and Novo Nordisk and advance our efforts to make diabetes management as simple as can be.

**Forbes: America’s Most Innovative Leaders**

Strong management and a focus on innovation have taken us a long way. We’re proud to see our Chairman and CEO Miles White recognized on exclusive lists such as Forbes’ 100 Most Innovative Leaders.

**Abbott Announces Share Repurchase Program**

Abbott has a long history of returning value to shareholders, and during the last 10 years, the company has delivered approximately $31 billion in cash to its shareholders through dividends and share repurchases.

**CNN: Scientist Discovers First New Strain of HIV in 19 Years**

CNN’s Anderson Cooper interviewed Dr. Mary Rodgers, who helped discover the first new strain of HIV in 19 years. As the leader in blood screening and infectious disease testing, our Global Viral Surveillance Program monitors for mutations of HIV and hepatitis viruses to ensure diagnostics tests remain up to date.

**The Future of Diagnosing Concussions**

Though we know more than ever about brain injuries, many still go undiagnosed. Findings from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study — one of the largest TBI research efforts of its kind — show our new blood test could help fill a gap in emergency rooms by identifying patients who could have otherwise gone undiagnosed.

**NCI: Chronic Diseases Affect Us All**

Chronic noncommunicable diseases (NCDs) such as diabetes and heart disease are now among the greatest health threats of our time. Finding new solutions to treat chronic diseases has long been a part of our work to help people live better, healthier lives. But we’re also working to address the underlying social and economic causes of NCDs. Learn more here.

**LIVING BETTER AND HEALTHIER**

For the latest on what’s happening at Abbott, visit us at www.abbottinvestor.com or follow us on Twitter and LinkedIn.